- Home
- SPHL vs NTRB Comparison
SPHL vs NTRB Comparison
Compare SPHL & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPHL
- NTRB
- Stock Information
- Founded
- SPHL 2002
- NTRB 2016
- Country
- SPHL Singapore
- NTRB United States
- Employees
- SPHL N/A
- NTRB N/A
- Industry
- SPHL Homebuilding
- NTRB Industrial Specialties
- Sector
- SPHL Consumer Discretionary
- NTRB Health Care
- Exchange
- SPHL Nasdaq
- NTRB Nasdaq
- Market Cap
- SPHL 54.5M
- NTRB 46.4M
- IPO Year
- SPHL 2024
- NTRB N/A
- Fundamental
- Price
- SPHL $3.12
- NTRB $4.11
- Analyst Decision
- SPHL
- NTRB
- Analyst Count
- SPHL 0
- NTRB 0
- Target Price
- SPHL N/A
- NTRB N/A
- AVG Volume (30 Days)
- SPHL 330.5K
- NTRB 26.3K
- Earning Date
- SPHL 02-21-2025
- NTRB 12-04-2024
- Dividend Yield
- SPHL N/A
- NTRB N/A
- EPS Growth
- SPHL 413.11
- NTRB N/A
- EPS
- SPHL 0.09
- NTRB N/A
- Revenue
- SPHL $11,020,429.00
- NTRB $2,021,771.00
- Revenue This Year
- SPHL N/A
- NTRB N/A
- Revenue Next Year
- SPHL N/A
- NTRB N/A
- P/E Ratio
- SPHL $35.66
- NTRB N/A
- Revenue Growth
- SPHL 112.84
- NTRB N/A
- 52 Week Low
- SPHL $2.71
- NTRB $2.22
- 52 Week High
- SPHL $7.16
- NTRB $9.60
- Technical
- Relative Strength Index (RSI)
- SPHL N/A
- NTRB 44.78
- Support Level
- SPHL N/A
- NTRB $3.90
- Resistance Level
- SPHL N/A
- NTRB $5.16
- Average True Range (ATR)
- SPHL 0.00
- NTRB 0.33
- MACD
- SPHL 0.00
- NTRB -0.01
- Stochastic Oscillator
- SPHL 0.00
- NTRB 27.04
About SPHL Springview Holdings Ltd Class A Ordinary Shares
Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.